Today (November 14), the A-share market closed with 90 stocks hitting their daily limit-up, excluding 19 ST stocks, leaving 71 limit-ups and 38 failed attempts, resulting in an overall limit-up rate of 70.31%.
**Limit-Up Battlefield: Furui Garnet Tops with Over 700 Million in Buy Orders** Statistics show that in terms of closing limit-up buy orders, China Fortune led with 1.5446 million lots, followed by Yongtai Energy, Shengli Co., and Furui Garnet with 1.0205 million, 776,000, and 646,000 lots, respectively.
In terms of consecutive limit-up days: - Furui Garnet and *ST Lü Kang secured seven consecutive limit-ups. - Sanmu Group achieved six. - Renmin Tongtai and Guosheng Tech (rights protection) recorded five. - Shengli Co., Antai Group, and *ST Jingfeng notched four. - ST Zhongzhu, *ST Zhengping (rights protection), Zhenai Meijia, and six others logged three. - China Fortune, Pingtan Development, Longzhou Co., and 13 others posted two. - Dongbai Group marked six limit-ups in eight days.
By buy-order value, 24 stocks exceeded 100 million yuan, with Furui Garnet, Pingtan Development, and Shengli Co. leading at 747 million, 430 million, and 430 million yuan, respectively.
Furui Garnet, the VC solvent leader in the electrolyte sector, secured seven consecutive limit-ups. The company disclosed on its investor platform that its subsidiary, Furui New Energy, has invested in a lithium battery electrolyte additive project. Current annual capacities include 40,000 tons of chloroethylene carbonate, 10,000 tons of crude vinylene carbonate, and 10,000 tons of refined vinylene carbonate.
**Sector Highlights: Pharmaceuticals, Natural Gas, and Lithium Batteries** 1. **Pharmaceutical Limit-Ups**: Renmin Tongtai, Zhong Sheng Pharma, Jiaying Pharma (rights protection), Kaikai Industrial, Jindike, and Kangzhi Pharma. - *Renmin Tongtai*: Optimizing strategies, deepening supplier collaboration, and expanding distribution rights for new and centralized procurement drugs. - *Zhong Sheng Pharma*: Its Angladivir tablets (brand: Anruiwei) treat adult influenza A, showing strong inhibition against resistant strains. - *Jiaying Pharma*: Focuses on R&D and production of traditional Chinese medicine.
2. **Natural Gas Limit-Ups**: Changchun Gas, Guoxin Energy, and Shouhua Gas. - *Changchun Gas*: Serves 1.8024 million users across eight cities and one national development zone, supplying 544 million cubic meters in 2024. - *Guoxin Energy*: Three gas-fired plants are improving, with reduced losses and higher output. - *Shouhua Gas*: Plans to add 21 deep coalbed methane wells in H2.
3. **Lithium Battery Limit-Ups**: Shida Shenghua, Fengyuan Co., Zhongyi Tech, and Furui Garnet. - *Shida Shenghua*: Fluorobenzene products are used in fluoroketones, pesticides, pharmaceuticals, and electrolyte additives. - *Fengyuan Co.*: Specializes in lithium-ion cathode materials and oxalate. - *Zhongyi Tech*: Holds patents for lithium-metal anodes in solid/liquid batteries.
**Top Performers: Four Stocks Net Over 100 Million in Buys** Stocks like Haichen Pharma, Dadongfang, Yunmei Energy, China Fortune, and Guoxin Energy featured on today’s top trading list. Four stocks saw net buys exceeding 100 million yuan: Aerospace Development (279 million), Shikong Tech (169 million), Kangzhi Pharma (142 million), and Lianhua Tech (124 million).
Among institutional trades, Shikong Tech, Hailu Heavy (rights protection), Zhongyi Tech, Lianhua Tech, and Kangzhi Pharma led with net buys of 208 million, 141 million, 113 million, 102 million, and 91.8537 million yuan, respectively.